Adjuvant sequential chemo and radiotherapy improves the oncological outcome in high risk XXXX .

@entity1204 @entity1 @entity5 @entity1349
OBJECTIVE: Evaluation of the impact of sequential chemoradiotherapy in high risk @entity1204 ( @entity1204 ). METHODS: Two hundred fifty-four @entity1 with stage IB grade 3, II and III @entity1204 (2009 FIGO staging), were included in this retrospective study. RESULTS: Stage I, II, and III was 24%, 28.7%, and 47.3%, respectively. Grade 3 @entity5 was 53.2% and 71.3% had deep myometrial invasion. One hundred sixty-five @entity1 (65%) underwent pelvic (+/- aortic) lymphadenectomy and 58 (22.8%) had nodal metastases. Ninety-eight @entity1 (38.6%) underwent radiotherapy, 59 (23.2%) chemotherapy, 42 (16.5%) sequential chemoradiotherapy, and 55 (21.7%) were only observed. After a median follow-up of 101 months, 78 @entity1 (30.7%) relapsed and 91 @entity1 (35.8%) died. Sequential chemoradiotherapy improved survival rates in @entity1 who did not undergo nodal evaluation (disease-free survival [DFS], p=0.040; @entity1349 [ @entity1349 ], p=0.024) or pelvic (+/- aortic) lymphadenectomy (DFS, p=0.008; @entity1349 , p=0.021). Sequential chemoradiotherapy improved both DFS (p=0.015) and @entity1349 (p=0.014) in stage III, while only a trend was found for DFS (p=0.210) and @entity1349 (p=0.102) in stage I-II @entity1204 . In the multivariate analysis, only age ( <= 65 years) and sequential chemoradiotherapy were statistically related to the prognosis. CONCLUSION: Sequential chemoradiotherapy improves survival rates in high risk @entity1204 compared with chemotherapy or radiotherapy alone, in particular in stage III.
